AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 251 min read$CLX

Clorox COO Chris Hyder receives 13,342 shares

Clorox COO Chris Hyder received 13,342 shares of common stock on September 23, 2026, at $83.94 per share, according to an SEC filing. Hyder now directly owns 90,202 shares. The transaction was reported as an acquisition.

Original reporting
stocktitan.net
Published Sep 25, 2026, 9:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CLX
Neutral
medium confidence
Mentioned
$CLX
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLXNeutralLow
01

Why it matters

The filing provides a fresh data point on insider sentiment, but the modest size limits market impact.

02

Market read

A modest insider purchase; likely limited short-term price effect.

03

What to watch

Potential upcoming product launches or cost initiatives not disclosed may influence the relevance of the insider buy.

Relevance 6/10Novelty 7/10Timing: post-transaction 09/23/2026

Background

Clorox Co. (ticker CLX) filed a Form 4 with the SEC reporting an insider purchase by its Chief Operating Officer.

Company-level read

Ticker impact

$CLXNeutralMedium confidence
Context

COO Chris Hyder purchased 13,342 shares of Clorox on 09/23/2026, disclosed via a Form 4 filing.

Expected impact

Potential slight upside pressure if market interprets as confidence, but limited impact.

Evidence & confidence

The filing is a primary source and first disclosure, but the transaction size is not large enough to drive a material price move.

Market effects

Sector

Minimal effect on consumer staples sector; insider activity is typical for large cap.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The purchase could be a routine compensation exercise rather than a strong bullish signal.

Key entities

  • Executive
    Chris Hyder

    Chief Operating Officer of Clorox Co.

Read at source← All news

Related articles

SEP 17
$CLXMedAI 8/10

Clorox stock hits 52-week low at 84.69 USD

Clorox (CLX) stock hit a 52-week low of $84.74, down 31.51% over the past year. Despite this, InvestingPro suggests it's undervalued with a 5.89% dividend yield. Q4 earnings per share were $1.66, missing estimates. UBS raised its price target to $105, maintaining a Neutral rating. Goldman Sachs and Morgan Stanley reported on broader consumer staples trends.

investing.com2 min
SEP 3
$CLXMed

Can Cost Savings Offset Inflation & Protect Clorox's Margins?

Clorox (CLX) reported a 520 basis point gross margin contraction in Q4 fiscal 2026 due to inflation and mix challenges. The company is focusing on cost savings and productivity initiatives to offset inflationary pressures, but expects margins to remain pressured in fiscal 2027. CLX shares have risen 5.2% in the past three months, with a forward P/E of 15.97X.

finance.yahoo.com2 min
AUG 21
$CLXMedAI 8/10

How GOJO Could Shape Clorox's Fiscal 2027 Growth and Margin Outlook

Clorox (CLX) expects fiscal 2027 net sales to rise 13-14%, with GOJO contributing 9.5 points. Q1 sales projected at 31-32%, including 15 points from GOJO. Adjusted earnings forecasted at $5.70-$6.00 per share, up 3-8%. Gross margin expected at 42%, with pressure from GOJO inventory costs and inflation. Integration costs and inflation pose near-term challenges.

tradingview.com3 min
AUG 21
$CLXMedAI 8/10

Is Clorox Stock Worth Buying as GOJO Growth Meets Margin Pressure?

Clorox (CLX) reports Q4 net sales of $1.95B, up 2% YoY, with GOJO contributing 10 percentage points. Fiscal 2027 sales expected to rise 13-14%, with adjusted EPS at $5.70-$6.00. Gross margins declined due to inflation and higher costs. Organic sales growth is muted, with ERP comparisons aiding growth. CLX trades at 17.9X forward earnings, below its sub-industry multiple.

tradingview.com3 min
AUG 14
$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.

yahoo.com6 min
AUG 11
$CLXMedAI 8/10

Clorox (CLX) Q4 2026 Earnings Call Transcript

Clorox (CLX) reported Q4 FY2026 net sales of $1.95B, down 2% (GOJO added about 10 points). Organic sales fell 13% and adjusted EPS was $1.66, down 42%. Gross margin was 41.3%. For FY2027, it guided organic sales growth of 3.5% to 4.5% and adjusted EPS of $5.70 to $6.00, citing inflation headwinds of $200M+.

fool.com6 min